pacman schreef op 20 januari 2021 11:18:
The C1 esterase inhibitor protein is required to control
the ‘complement’ and ‘contact’ systems, collections of
proteins in the blood that fight against infection and
cause inflammation. Patients with low levels of this
protein have excessive activity of these two systems
....
“Although this is an uncontrolled, small treatment
experience, the results demonstrate the potential
effectiveness of using Ruconest as an anti-inflammatory
approach to inhibit the complement and contact
systems after SARS-CoV-2 infection.
..
Prof. Bruno Giannetti, Pharming’s Chief Medical Officer,
comments: “Some of the dangerous biochemical
processes occurring during the worsening of a COVID-19
infection towards life-threatening pneumonia are
likely triggered by complement activation as part of
a systemic hyperinflammatory syndrome, otherwise
known as a ‘cytokine storm’. C1 inhibitor has numerous
anti-1 inflammatory properties, including inhibition of
the complement and contact systems. A compassionate
treatment in a few patients suffering from COVID-19
pneumonia was, therefore, scientifically sound and
these preliminary results are very encouraging.
Amongst others, we need to better identify the best
time point to start Ruconest treatment and the optimal
dosing regimen. The planned multinational study
under the leadership of the University of Basel is aimed
at providing this information.”